Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omadacycline versus moxifloxacin for adult community-acquired bacterial pneumonia
CTR20232385Phase 3Completed
- Sponsor
- Sinopep-Allsino Biopharmaceutical
- Start
- Aug 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of omadacycline, moxifloxacin in community acquired pneumonia (CAP), sponsored by Sinopep-Allsino Biopharmaceutical. Started Aug 2023; status: completed.
02
Drugs
omadacyclinemoxifloxacin
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on CTR20232385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232385.